摘要
黑色素瘤是一种恶性的黑色素细胞肿瘤,我国黑色素瘤的发病率逐年攀升,而晚期黑色素瘤在过去几十年里一直没有有效的治疗方法,放疗、化疗及传统免疫治疗效果均不理想,患者预后极差。近年来,随着靶向药物(BRAF抑制剂)在晚期黑色素瘤的治疗上取得突破性进展,为晚期黑色素瘤内科治疗开启了新的篇章。本文通过对国内外具有代表性的临床试验结果的分析,就目前BRAF抑制剂用于治疗晚期黑色素瘤的研究进展作一综述,并初步探讨BRAF抑制剂在晚期黑色素瘤患者中的全程管理问题。
Melanoma is the most aggressive form of skin tumor caused by excessive proliferation of the abnormal melanocytes with an increasing incidence in recent years in China. However,patients with advanced melanoma had very poor prognosis by traditional therapies. The discovery of prevalent BRAF V600 mutation driving proliferation offers an opportunity to test this oncogene-target therapy for melanoma. Since 2011,the development of BRAF inhibitor significantly improved the outcome of advanced melanoma treatment,which have brought a hope to the advanced melanoma therapy. This article reviews the mechanism and the current clinical application of BRAF inhibitor from clinical trials in advanced melanoma. In addition,this review will also focus on safety of BRAF inhibitor and treatment selection to obtain maximal benefit in clinical practices.
出处
《临床肿瘤学杂志》
CAS
北大核心
2018年第1期73-78,共6页
Chinese Clinical Oncology
